{"id":"pantoprazole-for-approximately-9-weeks","safety":{"commonSideEffects":[{"rate":"12-13%","effect":"Headache"},{"rate":"8-12%","effect":"Diarrhea"},{"rate":"7-9%","effect":"Nausea"},{"rate":"5-6%","effect":"Abdominal pain"},{"rate":"3-4%","effect":"Vomiting"},{"rate":"3-4%","effect":"Flatulence"}]},"_chembl":{"chemblId":"CHEMBL1502","moleculeType":"Small molecule","molecularWeight":"383.38"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Pantoprazole is a proton pump inhibitor (PPI) that binds to and inactivates the H+/K+-ATPase enzyme on the secretory surface of gastric parietal cells. This blocks the final step of gastric acid production, significantly reducing both basal and stimulated acid secretion. It is used to treat acid-related gastrointestinal disorders by maintaining elevated gastric pH.","oneSentence":"Pantoprazole irreversibly inhibits the proton pump in gastric parietal cells, reducing gastric acid secretion.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:25:28.085Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Gastroesophageal reflux disease (GERD)"},{"name":"Peptic ulcer disease"},{"name":"Zollinger-Ellison syndrome"},{"name":"Acid-related gastrointestinal conditions"}]},"trialDetails":[{"nctId":"NCT00195208","phase":"PHASE3","title":"Study Comparing a Pantoprazole Formulation to the Currently Marketed Tablet for GERD and Erosive Esophagitis","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2005-06","conditions":"Gastroesophageal Reflux, Esophagitis","enrollment":97},{"nctId":"NCT00141817","phase":"PHASE3","title":"Study Evaluating Pantoprazole in Children With GERD","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2005-08","conditions":"Gastroesophageal Reflux","enrollment":41}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Pantoprazole for approximately 9 weeks","genericName":"Pantoprazole for approximately 9 weeks","companyName":"Wyeth is now a wholly owned subsidiary of Pfizer","companyId":"wyeth-is-now-a-wholly-owned-subsidiary-of-pfizer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Pantoprazole irreversibly inhibits the proton pump in gastric parietal cells, reducing gastric acid secretion. Used for Gastroesophageal reflux disease (GERD), Peptic ulcer disease, Zollinger-Ellison syndrome.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}